

## Press release

## Transparency Declaration by FMR LLC Regulated information published in view of the transparency directive

leper, Belgium – October 13th, 2016, 17.40 hrs CET

On Tuesday, October 11<sup>th</sup>, 2016, Melexis received a transparency declaration from FMR LLC according to the stipulations of the Law of May 2<sup>nd</sup>, 2007. The declaration is related to the actualization of the notification of March 22<sup>nd</sup>, 2013. The reason of notification is the threshold crossing of one of the subsidiaries of FMR LLC.

The declaration dated October 11<sup>th</sup>, 2016 contains following information:

- Reason for the notification: Acquisition or disposal of voting securities or voting rights
- Notification by: a parent undertaking or a controlling person
- Persons subject to the notification requirement: FMR LLC, (The Corporation Trust Center, 1209 Orange Street, Wilmington, New Castle County, Delaware, 19801)
- Date on which the threshold is crossed: 3 October 2016
- Threshold that is crossed: 5%
- Denominator: 40.400.000

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to securities	Linked to securities	Not linked to securities
FMR LLC	4.032.132	0		0.00%	
FMR Co. Inc		2.983.500		7.38%	
Fidelity Management & Research (Hong Kong) Limited		4.140		0.01%	
Subtotal	4.032.132	2.987.640		7.40%	
		2.987.640	0	7.40%	0.00%

Notified details



- Full chain of controlled undertakings through which the holding is effectively held: The holdings attributable to FMR LLC arise from holdings of various undertakings for collective investment that are managed by FMR Co. Inc and Fidelity Management & Research (Hong Kong) Limited, each of which are entities that are subsidiaries of and controlled by FMR LLC. These undertakings for collective investment have granted FMC LLC discretionary power to vote the securities in accordance with the FMR LLC board proxy voting policy. FMR LLC is not a controlled undertaking.
- Additional information: FMR Co. INC is a subsidiary undertaking of Fidelity Management & Research Company, which itself is a subsidiary undertaking of FMR LLC (the ultimate parent company), and is above a notifiable threshold as of 03/10/2016.
- The declaration can be found on the Melexis website through this link: <u>https://www.melexis.com/en/investors/share-information/transparency-declarations</u>

For further information Investor Relations Phone: +32 13 67 07 79 Fax: +32 13 67 21 34 E-mail: investor@melexis.com

## About Melexis

Combining a passion for technology with truly inspired engineering, Melexis designs, develops and delivers innovative micro-electronic solutions that enable designers to turn ideas into applications that support the best imaginable future. The company's advanced mixed-signal semiconductor sensor and actuator components address the challenges of integrating sensing, driving and communication into next-generation products and systems that improve safety, raise efficiency, support sustainability and enhance comfort. Melexis is headquartered in Belgium and employs over 1,100 people in 19 locations worldwide. The company is publicly traded on Euronext Brussels (MELE). For more information, visit www.melexis.com

## Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forward-looking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.